Physician profile
Kathryn E Seba
NPI 1235737057
$1,998.08
in general payments reported to CMS, 2019-2025
19 companies · $632 in 2025
The $632 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.56 · 2022: $221 · 2023: $751 · 2024: $382 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,708 · Education: $56.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,707.67 |
| Education | $56.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $492.86 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $433.84 | 2022-2025 | Dupixent |
| Aerin Medical INC. | $284.44 | 2023-2025 | |
| Genzyme Corporation | $245.78 | 2023-2025 | |
| Alk-Abello, INC | $109.66 | 2023-2025 | Grastek, Odactra, Ragwitek |
| Smith+Nephew, INC. | $58.54 | 2025 | Tula |
| Sanofi-Aventis U.S. LLC | $56.99 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $54.02 | 2025 | Neffy |
| Glaxosmithkline, LLC. | $35.84 | 2025 | Nucala |
| Hikma Pharmaceuticals USA | $31.36 | 2022-2024 | Ryaltris |
| Phadia US INC. | $29.12 | 2023-2024 | Immunocap |
| Kaleo, INC. | $26.73 | 2023 | Auvi-Q |
| Astrazeneca Pharmaceuticals LP | $25.26 | 2025 | Tezspire |
| Merck Sharp & Dohme LLC | $24.09 | 2023 | |
| Amgen INC. | $22.55 | 2025 | Tezspire |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $20.98 | 2023 | Codman Isocool Aht, Microfrance, Integra Duo |
| Inspire Medical Systems, INC. | $17.47 | 2023 | Inspire |
| Acclarent, INC | $15.99 | 2022 | |
| Genentech USA, INC. | $12.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Seba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.